Richards et al in 2015 reported that HOXA11‐AS expression levels were significantly decreased in human epithelial ovarian cancer than normal ovarian tissues, indicating that HOXA11‐AS may serve as a tumor suppressor in epithelial ovarian cancer.4 Instead of a tumor suppressor, HOXA11‐AS was served as a tumor accelerator in serous ovarian cancer (SOC), which is the most common histological form of epithelial ovarian cancer.34 HOXA11‐AS expression in SOC tissue was found to be dramatically higher (77‐fold) than that of normal ovarian tissues by qRT‐PCR. This evidence concerns the gene HOXA11 and ovarian serous adenocarcinoma.